Medical Health & Life Science Research News

New report shares details about the global market for alpha- antitrypsin deficiency therapeutics review H2 2016

The report provides comprehensive information on the therapeutics under development for Alpha- Antitrypsin Deficiency, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report provides an overview of key players involved in therapeutic development for Alpha- Antitrypsin Deficiency and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


 This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

- Agency -.

Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis

Drugs Profile Discussed in this Research:

ALN-AAT, alpha-1 proteinase inhibitor (human), alpha-1 proteinase inhibitor (human) second generation, ANN-001, ARC-AAT, CT-2009, DB-027, Drugs for Alpha-1 Antitrypsin Deficiency, Gene Therapy to Activate Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency, Gene Therapy to Activate Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency, ISIS-AATRx, Oligonucleotides to Activate Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency, POL-6014, rAAV2-CB-hAAT, Recombinant A1PI Recombinant A1PI, Recombinant Human Alpha-1 Antitrypsin,

Companies Discussed/Mentioned in this Research:

Adverum Biotechnologies, Alnylam Pharmaceuticals, Applied Genetic Technologies Corporation, Arrowhead Pharmaceuticals, Carolus Therapeutics, Cevec Pharmaceuticals GmbH, Dicerna Pharmaceuticals, Digna Biotech, Editas Medicine, Grifols, Inhibrx, Intellia Therapeutics, International Stem Cell Corporation, Ionis Pharmaceuticals, Kamada Ltd., Polyphor Ltd.,


  • The report provides a snapshot of the global therapeutic landscape of Alpha- Antitrypsin Deficiency
  • The report reviews pipeline therapeutics for Alpha- Antitrypsin Deficiency by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RandD brief, licensing and collaboration details and other developmental activities
  • The report reviews key players involved Alpha- Antitrypsin Deficiency  therapeutics and enlists all their major and minor projects
  • The report assesses Alpha- Antitrypsin Deficiency   therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Alpha- Antitrypsin Deficiency

Reasons to access

  • Gain strategically significant competitor information, analysis, and insights to formulate effective RandD strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Alpha- Antitrypsin Deficiency
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Alpha- Antitrypsin Deficiency   pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

News From

ReportsnReports - Industry Trends & ForecastsReportsnReports
Category: Market Research Publishers and RetailersCompany profile: provides market research reports to industries, individuals and organizations with an objective of helping them in their decision-making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets.